Greenwich LifeSciences
GLSI
24 hedge funds and large institutions have $4.75M invested in Greenwich LifeSciences in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
4% more funds holding
Funds holding: 23 → 24 (+1)
0.71% less ownership
Funds ownership: 4.89% → 4.18% (-0.71%)
22% less capital invested
Capital invested by funds: $6.06M → $4.75M (-$1.31M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$117K |
| 2 |
Squarepoint
New York
|
+$103K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.8K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$12.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$639 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$585K |
| 2 |
Renaissance Technologies
New York
|
-$234K |
| 3 |
Millennium Management
New York
|
-$152K |
| 4 |
HF
HRT Financial
New York
|
-$97K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$45K |
GLSI Hedge Fund Activity: Q3 2023 in Review
24 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Greenwich LifeSciences (GLSI) for Q3 2023, worth a combined $4.75M — down 22% from $6.06M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GLSI positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 9 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $117K. The largest seller was Vanguard Group, cutting an estimated $585K.
- 24 institutional investors held Greenwich LifeSciences (GLSI) as of Q3 2023, up from 23 in Q2 2023.
- Funds reported $4.75M of Greenwich LifeSciences stock for Q3 2023, down 22% quarter-over-quarter.
- 2 funds opened new Greenwich LifeSciences positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Greenwich LifeSciences buyer in Q3 2023 was GSA Capital Partners, an estimated $117K added.
- The largest Greenwich LifeSciences seller in Q3 2023 was Vanguard Group, an estimated $585K sold.
Based on aggregated 13F filings for Q3 2023.